BriaCell Therapeutics Corp.
BCTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BCTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCTX
BriaCell Therapeutics Corp. (BCTX) is a clinical-stage biotechnology company developing targeted immunotherapies for solid tumors, with its lead candidate Bria-IMT in a Phase 3 trial and a cash position of $6.9M as of April 30, 2026.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Apr 30, 2026.
Tracking 2 clinical trials · 1 catalyst for BriaCell Therapeutics Corp..
BriaCell Therapeutics Corp. (BCTX) is a clinical-stage biotechnology company developing targeted immunotherapies for solid tumors, with its lead candidate Bria-IMT in a Phase 3 trial and a cash position of $6.9M as of April 30, 2026.
- Lead product candidate Bria-IMT is in a Phase 3 randomized, open-label study versus physicians' choice [sec_mda · as of 2026-06-09].
- Cash and equivalents of $6.9M as of April 30, 2026 [latest reported financials].
- Net loss of $7.2M for the period ended April 30, 2026 [latest reported financials].
- Accumulated deficit of $134.3M as of April 30, 2026 [sec_mda · as of 2026-06-09].
- Positive working capital of $21.8M as of April 30, 2026 [sec_mda · as of 2026-06-09].
What works
- Positive working capital of $21.8M as of April 30, 2026 provides near-term liquidity to fund operations [sec_mda · as of 2026-06-09].
- Phase 3 trial of Bria-IMT is advancing, with topline data expected in 2028, representing a potential value inflection point [sec_mda · as of 2026-06-09].
- Clinical trial expenses increased to $12.6M in 2026 from $9.7M in 2025, reflecting expanded development activities [sec_mda · as of 2026-06-09].
What to weigh
- Cash and equivalents of only $6.9M as of April 30, 2026 may be insufficient to fund operations without additional capital [latest reported financials].
- Accumulated deficit of $134.3M as of April 30, 2026 reflects a history of losses with no current revenue [sec_mda · as of 2026-06-09].
- The company has a going concern uncertainty and must raise additional capital to continue operations [sec_mda · as of 2026-03-10].
- Net loss of $7.2M for the period ended April 30, 2026 indicates ongoing cash burn [latest reported financials].
From the filings
Quoted directly from source documents.
Accumulated deficit as of April 30, 2026
“accumulated deficit of $134,339,456”
SEC MD&A · June 9, 2026
Going concern uncertainty
“The financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.”
SEC MD&A · March 10, 2026
Catalyst timeline
- 2028-06-01 · Phase3_Topline · bria-imt — Phase 3 Topline: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice — Topline data from the Phase 3 trial of Bria-IMT will be a key value inflection point for the company.
Risks & what to watch (4)›
Key risks
- Going concern risk — The company may need to curtail or cease operations if it cannot raise additional capital [sec_mda · as of 2026-03-10].
- Cash runway limited — Cash of $6.9M as of April 30, 2026 may not sustain operations until Phase 3 data in 2028 [latest reported financials].
- Clinical trial failure risk — Phase 3 trial of Bria-IMT may fail to meet endpoints, leading to loss of value [sec_mda · as of 2026-06-09].
- Dilution from capital raises — Future equity financings to fund operations could dilute existing shareholders [sec_mda · as of 2026-03-10].
What to watch
- Phase 3 topline data for Bria-IMT expected in 2028 [sec_mda · as of 2026-06-09].
- Ability to raise additional capital to extend cash runway beyond $6.9M [sec_mda · as of 2026-03-10].
- Progress of next-generation platform Bria-OTS+ across solid tumor indications [sec_mda · as of 2026-03-10].
- Changes in working capital and cash burn rate in upcoming quarterly filings [sec_mda · as of 2026-06-09].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BriaCell Therapeutics Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BriaCell Therapeutics Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
9.7 months
OCF -$7M · Net income -$7M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~641d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$662K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 73,915 | $310K |
| iridian asset management llc/ct | 65,000 | $272K |
| luminarx capital management lp | 15,000 | $63K |
| morgan stanley | 3,021 | $13K |
| national bank of canada /fi/ | 802 | $3K |
| federation des caisses desjardins du quebec | 455 | $2K |
| td waterhouse canada inc. | 19 | $78 |
| group one trading llc | 16 | $67 |
| caitong international asset management co., ltd | 7 | $29 |
| hhm wealth advisors, llc | 6 | $26 |
Showing top 10 of 12 institutional holders of BriaCell Therapeutics Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.5%
- Days to cover
- 3.1
- Shares short
- 472,347
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for BriaCell Therapeutics Corp.?
BriaCell Therapeutics Corp. (BCTX) is a clinical-stage biotechnology company developing targeted immunotherapies for solid tumors, with its lead candidate Bria-IMT in a Phase 3 trial and a cash position of $6.9M as of April 30, 2026.
What is BriaCell Therapeutics Corp.'s next catalyst?
BriaCell Therapeutics Corp.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice" — expected June 1, 2028.
Who is the CEO of BriaCell Therapeutics Corp.?
Dr. William V. Williams FCPA, M.D. is the chief executive officer of BriaCell Therapeutics Corp. (BCTX).
Where is BriaCell Therapeutics Corp. headquartered?
BriaCell Therapeutics Corp. (BCTX) is headquartered in West Vancouver, BC, Canada.
What therapeutic areas does BriaCell Therapeutics Corp. focus on?
BriaCell Therapeutics Corp. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.